Impact of different model structure and prior distribution in continual reassessment method (Q5087922): Difference between revisions

From MaRDI portal
Set OpenAlex properties.
ReferenceBot (talk | contribs)
Changed an Item
 
Property / cites work
 
Property / cites work: Optimal Bayesian-feasible dose escalation for cancer phase I trials / rank
 
Normal rank
Property / cites work
 
Property / cites work: Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities / rank
 
Normal rank
Property / cites work
 
Property / cites work: A Curve‐Free Method for Phase I Clinical Trials / rank
 
Normal rank
Property / cites work
 
Property / cites work: Bayesian model averaging: A tutorial. (with comments and a rejoinder). / rank
 
Normal rank
Property / cites work
 
Property / cites work: Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer / rank
 
Normal rank
Property / cites work
 
Property / cites work: Group Sequential and Adaptive Designs – A Review of Basic Concepts and Points of Discussion / rank
 
Normal rank
Property / cites work
 
Property / cites work: Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials / rank
 
Normal rank

Latest revision as of 13:36, 29 July 2024

scientific article; zbMATH DE number 7552563
Language Label Description Also known as
English
Impact of different model structure and prior distribution in continual reassessment method
scientific article; zbMATH DE number 7552563

    Statements

    Impact of different model structure and prior distribution in continual reassessment method (English)
    0 references
    0 references
    0 references
    0 references
    4 July 2022
    0 references
    0 references
    clinical trials
    0 references
    dose-response models
    0 references
    maximum tolerated dose
    0 references
    phase I
    0 references
    0 references